Articles On Genetic Signatures (ASX:GSS)

The market may be struggling on Thursday, but that hasn’t stopped the Genetic Signatures Ltd (ASX: GSS) share price from charging higher. In afternoon trade the specialist molecular diagnostics company’s shares are up over 5% to $1.99 Why...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a disappointing note. At the time of writing the benchmark index is down 0.9% to 5,819.5 points. Four shares that have not let that hold them back a...

ShareCafeGenetic Signatures – ShareCafe Hidden Gems Webinar Presentation   Presenter – John Melki – CEO & Director – Genetic Signatures has released a suite of real-time PCR based products for the routine detection of infectious diseas...

ShareCafeHidden Gems Webinar Recap – OSL, MDC, CYP, GSS   We continue to unearth small-cap companies as part of our Hidden Gems webinar series. Catch up on the full webinar with presentations from Oncosil Medical (ASX:OSL), Medlab Clinical...

By Tim Boreham, Editor, The New Criterion The ASX biotechs surfing the COVID-19 story Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the d...

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with...

Two COVID-19 antibody kits have failed post-market testing, raising more questions about the 20 point-of-care kits approved for sale in Australia. Four of the 20 point-of-care tests (PoCT) available in Australia have now failed independent...

Less than a fortnight ago Finfeed noted Genetic Signature Ltd’s (ASX: GSS) news that it had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-2), the virus that causes COVID-19. Managem...

This could be the best investment opportunity that Australian investors have had in a decade. Those are the words of portfolio managers from Perennial Value Management. According to its latest monthly report, the investment company’s portf...

A new rapid testing kit that can detect the virus which causes Covid-19 has been given the tick of approval from the Therapeutic Goods Administration (TGA). Genetic Signatures' (ASX: GSS) SARS-CoV-2 Detection Kit has been approved for inc...

Australian biotech Genetic Signatures’ (ASX:GSS) is now able to start selling its recently developed COVID-19 diagnostic kit, after it was approved for sale in Australia. The EasyScreen SARS-CoV-2 Detection Kit has been approved to be liste...

14 Apr 2020 - Genetic Signatures (ASX:GSS) has received notice from the Therapeutic Goods Administration (“TGA”) that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to…

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

The market for COVID-19 diagnostic kits is much broader than just the health sector, as miners and other industries begin to compete for tests with governments. But where diagnostic tests normally require at minimum several months of patien...

Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price actio...

Specialist molecular diagnostics company Genetic Signatures (ASX: GSS) is sending its first shipments of a new Covid-19 testing kit to labs in Europe and Australia, with its manufacturing facilities in Sydney gearing up for "anticipated ini...

Shares in Genetic Signatures Limited (ASX:GSS) were up 50% at one stage on Monday morning as management announced that the company had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-...

Molecular diagnostics company Genetic Signatures (ASX: GSS) has submitted a European CE in vitro diagnostics registration application for its new 3base EasyScreen coronavirus detection kit. The kit complements the company’s existing EasyScr...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

As the coronavirus death toll rises to more than 1,000 and the World Health Organisation labels it a global health emergency, share markets are feeling the impact of the outbreak with Australian ASX-listed stocks not immune to the damage. C...

The Aussie market wavers around yesterdays closing mark, following marginal shifts in US indices overnight. By mid-session, the benchmark ASX 200 was just ten points below yesterday’s close of 7,031 points. The US industrial index, the...

We hate to sound like an old school report, but it’s been a year of steady and solid progress for the maker of non-invasive cardiac and pulmonary measuring devices, especially in its key target market of China. Achievements include record r...

As the saying goes, if you can make it in New York you can make it anywhere. But for the home-grown molecular diagnostics house, cracking it in Australia has been the acid test of its greater abilities. “The Australian diagnostic market is...

Health care sector During the past several years, the Australian Health Care Sector had seen rapid development, and as a result it stands out as one of the best health care systems in the world, delivering safe, effective and affordable hea...

This year has been a positive one for ASX small caps. According to Bloomberg, the average small cap has gained just under 5 per cent and some of the major sectors have seen double digit percentage gains. One example is the health sector whi...